1998
Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma
Zalupski M, Shields A, Philip P, Kraut M, LoRusso P, Heilbrun L, Vaitkevicius V. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Investigational New Drugs 1998, 16: 93-96. PMID: 9740550, DOI: 10.1023/a:1006087114621.Peer-Reviewed Original ResearchConceptsPancreatic carcinomaBroad preclinical antitumor activityUntreated advanced pancreatic cancerAdvanced pancreatic cancerAdvanced pancreatic carcinomaPhase II trialSchedule of administrationPreclinical antitumor activityModerate neutropeniaPredictable toxicityII trialMajor toxicityClinical efficacyMild neurotoxicityPancreatic cancerClinical developmentPatientsPyrazoloacridinePhase IAntitumor activitySolid tumor selectivityTumor selectivityCarcinomaDoseToxicity
1997
Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma
Zalupski M, Philip P, LoRusso P, Shields A. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemotherapy And Pharmacology 1997, 40: 225-227. PMID: 9219505, DOI: 10.1007/s002800050650.Peer-Reviewed Original ResearchConceptsColorectal cancerBroad preclinical antitumor activityUntreated advanced colorectal cancerPhase II studyAdvanced colorectal cancerPhase II trialSchedule of administrationAdvanced colorectal carcinomaPreclinical antitumor activityPredictable toxicityII trialII studyClinical efficacyColorectal carcinomaClinical developmentPatientsPyrazoloacridinePhase IAntitumor activitySolid tumor selectivityTumor selectivityCancerDoseToxicityMyelosuppression
1990
Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.
LoRusso P, Wozniak A, Polin L, Capps D, Leopold W, Werbel L, Biernat L, Dan M, Corbett T. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Research 1990, 50: 4900-5. PMID: 2165850.Peer-Reviewed Original ResearchMeSH KeywordsAcridinesAdenocarcinomaAnimalsAntineoplastic AgentsCarcinoma, Intraductal, NoninfiltratingCell SurvivalColonic NeoplasmsDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorMiceMice, Inbred BALB CMice, Inbred C3HMice, Inbred C57BLMice, Inbred DBAMice, Inbred StrainsPancreatic NeoplasmsPyrazolesTumor Cells, CulturedConceptsInfusional therapyCentral nervous system toxicityNervous system toxicityDisk diffusionPreclinical toxicology evaluationColon adenocarcinoma 38Log cell killMain toxicityBolus therapySystem toxicityCellular cytotoxicityMurine L1210 leukemiaSolid tumorsInfusion studiesTotal doseCell killAntitumor efficacyHuman investigationsL1210 leukemiaAgar disk diffusionTherapySolid tumor selectivityTumor selectivityToxicology evaluationToxicityActivity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice
Mucci-LoRusso P, Polin L, Biernat L, Valeriote F, Corbett T. Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice. Investigational New Drugs 1990, 8: 253-261. PMID: 2177044, DOI: 10.1007/bf00171834.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsCarcinoma, Intraductal, NoninfiltratingColonic NeoplasmsDrug Screening Assays, AntitumorEllipticinesFemaleHumansInjections, IntravenousLeukemia L1210MaleMammary Neoplasms, ExperimentalMiceMice, Inbred StrainsNeoplasm TransplantationNeoplasms, ExperimentalPancreatic Neoplasms